Mylan (MYL) Unit Launches Generic Viramune Tabs

Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nevirapine Tablets USP, 200 mg.

This product is the generic version of Boehringer Ingelheim's Viramune and is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept
• EU opens antidumping review of Chinese silicon metal imports
• DigitalBridge to delist preferred stock from NYSE ahead of SoftBank deal